Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis

IRB. 2011 Jul-Aug;33(4):10-7.

Authors

Charles M Heilig¹, David Chia, Wafaa M El-Sadr, Yael Hirsch-Moverman, William R Mac Kenzie, Jussi Saukkonen, Margarita E Villarino, Nesri Padayatchi

Affiliation

¹ Division of Tuberculosis Elimination, U.S. Centers for Disease Control and Prevention, Atlanta, GA, USA.

PMID: 21932482

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Acetamides / adverse effects
Acetamides / therapeutic use
Antitubercular Agents / adverse effects
Antitubercular Agents / therapeutic use
Humans
Linezolid
Oxazolidinones / adverse effects
Oxazolidinones / therapeutic use
Placebos
Randomized Controlled Trials as Topic / ethics*
Risk Assessment
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Acetamides
Antitubercular Agents
Oxazolidinones
Placebos
Linezolid